Genmab A+s

Cormorant Pharmaceuticals Ab

Medarex Inc.

Debra Hudson

Paul Parren

Ole Baadsgaard

Jessica Teeling

Jørgen Petersen

Jorgen Petersen

Marcus A Van Dijk

Jan G J Van De Winkel

Ole D Baadsgaard

Ole D M Sc Baadsgaard

Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Methods of treating cancer with human monoclonal antibodies against interleukin 8 (IL-8)

Human monoclonal antibodies against interleukin 8 (IL-8)

Methods of treating cancer with human monoclonal antibodies against interleukin 8

Human monoclonal antibodies which bind specifically to Fc alpha receptor (CD89), including monoclonal antibodies which react specifically to Fc receptor for IgA of human effector cells are disclosed. The binding agents, e.g., antibodies are useful for targeting human effector cells (e.g. macrophages) against a target cell (e.g. a cancer cell, an infectious agent, etc.). For this purpose, bifunctional antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc-alpha receptor antibody and the binding region of a target-specific antibody. Targeted effector cells can specifically lyse target cells.

Human monoclonal antibodies to FC alpha receptor (CD89)

Growing community of inventors

Livermore, CA, United States of America

Debra Hudson